molecular-glue-discovery-agent

name	molecular-glue-discovery-agent
description	AI-powered molecular glue discovery for targeted protein degradation, enabling neo-substrate recruitment and undruggable target degradation through E3 ligase interface modulation.
measurable_outcome	Execute skill workflow successfully with valid output within 15 minutes.
allowed-tools	["read_file","run_shell_command"]

Molecular Glue Discovery Agent

The Molecular Glue Discovery Agent enables AI-driven discovery of molecular glue degraders that induce protein-protein interactions between E3 ligases and neo-substrates for targeted protein degradation. Unlike PROTACs, molecular glues are smaller, more drug-like molecules that can access previously "undruggable" targets through induced proximity mechanisms.

When to Use This Skill

• When discovering new molecular glue scaffolds.
• For identifying neo-substrate targets for existing glues.
• To design glues for specific E3-substrate pairs.
• When optimizing glue selectivity and potency.
• For virtual screening of glue candidates.

Core Capabilities

1. Glue Scaffold Discovery: Identify novel molecular glue chemotypes.

2. Neo-Substrate Prediction: Predict proteins degraded by glues.

3. Interface Modeling: Model E3-glue-substrate ternary interfaces.

4. Selectivity Optimization: Design for specific substrate profiles.

5. SAR Analysis: Structure-activity relationship modeling.

6. Virtual Screening: Screen compounds for glue activity.

Molecular Glue Mechanisms

Class	E3 Ligase	Mechanism	Example
IMiDs	CRBN	Degron recognition	Lenalidomide
CELMoDs	CRBN	Enhanced IKZF binding	Iberdomide
DCAF15 Glues	DCAF15	Splicing factor degradation	Indisulam
CDK12 Glues	DDB1-CRBN	Cyclin K degradation	CR8 derivatives
β-catenin Glues	Novel	WNT pathway targets	Emerging

Key Neo-Substrates

Substrate	Glue Class	Disease Relevance
IKZF1/3	IMiDs	Multiple myeloma
CK1α	Lenalidomide	MDS del(5q)
GSPT1	CC-885	AML
RBM39	Indisulam	Solid tumors
Cyclin K	CR8	Cancer
SALL4	Thalidomide	Teratogenicity

Workflow

1. Input: Target substrate, E3 ligase, screening library.

2. Interface Analysis: Model E3 surface and potential binding sites.

3. Virtual Screening: Screen compounds for interface binding.

4. Glue Scoring: Predict neo-substrate recruitment potential.

5. Selectivity Analysis: Predict off-target degradation.

6. Optimization: Iterative design for potency/selectivity.

7. Output: Ranked glue candidates with predicted profiles.

Example Usage

User: "Discover molecular glues that degrade IKZF1 through CRBN with improved selectivity over IKZF3."

Agent Action:

python3 Skills/Drug_Discovery/Molecular_Glue_Discovery_Agent/discover_glue.py \
    --target_substrate IKZF1 \
    --e3_ligase CRBN \
    --selectivity_against IKZF3 \
    --scaffold_library imid_derivatives.sdf \
    --interface_model crbn_ikzf1_complex.pdb \
    --n_candidates 100 \
    --output glue_discovery/

Glue Design Parameters

Parameter	Consideration	Optimization
Interface Complementarity	E3-substrate fit	Shape/electrostatics
Degron Recognition	Substrate degron motifs	Motif compatibility
Binding Cooperativity	Positive cooperativity	Enhanced ternary
Selectivity	Off-target degradation	Substrate specificity
Drug Properties	MW, solubility, permeability	Standard optimization

Output Components

Output	Description	Format
Glue Candidates	Ranked molecules	.sdf, SMILES
Predicted Substrates	Neo-substrate profiles	.csv
Interface Models	Ternary complex structures	.pdb
Selectivity Scores	On-target vs off-target	.csv
Degradation Predictions	DC50, Dmax estimates	.csv
SAR Analysis	Structure-activity trends	.json

AI/ML Components

Interface Prediction:

• Protein-protein docking
• Molecular surface analysis
• Deep learning interface scoring

Neo-Substrate Discovery:

• Degron motif prediction
• Proteome-wide screening
• Structural similarity to known substrates

Glue Optimization:

• Generative chemistry
• Multi-objective optimization
• Active learning for synthesis prioritization

Glue vs PROTAC Comparison

Feature	Molecular Glue	PROTAC
Molecular Weight	<500 Da	700-1500 Da
Target Discovery	Serendipitous/AI	Rational
Selectivity	Can be exquisite	Often broader
Substrate Range	Induced neo-substrates	Direct binders
Oral Bioavailability	Generally better	Challenging

Clinical Pipeline (2026)

Drug	Mechanism	Target	Phase
Iberdomide (CC-220)	CELMoD	IKZF1/3, Aiolos	Phase 3
Mezigdomide (CC-92480)	CELMoD	IKZF1/3	Phase 3
Golcadomide (CC-99282)	CELMoD	IKZF1/3	Phase 2
CFT7455	IKZF1/3	IKZF1/3	Phase 1

Degron Motif Analysis

Degron Type	Sequence Features	E3 Recognition
Zinc Finger	C2H2 ZF domain	CRBN-IMiD
Phosphodegron	pSer/pThr motifs	SCF E3s
N-degron	N-terminal residues	UBR1/2
Hydrophobic	Exposed hydrophobics	Quality control

Prerequisites

• Python 3.10+
• RDKit, Molecular modeling tools
• AlphaFold2/3, docking software
• Deep learning frameworks
• Protein structure databases

Related Skills

• PROTAC_Design_Agent - Bifunctional degraders
• TPD_Ternary_Complex_Agent - Complex modeling
• Virtual_Screening_Agent - High-throughput screening
• Protein_Protein_Docking_Agent - PPI modeling

Discovery Strategies

Strategy	Approach	Success Examples
Phenotypic Screening	Degradation readout	IMiDs, indisulam
Target-Based	E3-substrate docking	Rational glues
Chemoproteomics	Pull-down identification	Neo-substrate discovery
AI-Guided	Computational prediction	Emerging

Special Considerations

1. Polypharmacology: Glues often degrade multiple substrates
2. Species Differences: Neo-substrates may differ across species
3. Resistance: Substrate mutations, E3 downregulation
4. Toxicity: Off-target degradation (e.g., SALL4)
5. Hook Effect: Less common than PROTACs

Quality Control

Metric	Purpose	Threshold
Interface Score	Complex stability	>0.6
Cooperativity	Enhanced binding	>1.5
Selectivity Index	On/off-target ratio	>10
Drug-likeness	Developability	Lipinski compliant

Future Directions

Direction	Status	Potential
New E3 Ligases	Active research	Expanded target space
Protein-Protein Glues	Emerging	Beyond degradation
AI-First Discovery	Advancing	Reduced serendipity
Combination Glues	Conceptual	Multi-target degradation